

Person with cancer—lung cancer immunohistochemistry type, code N[N]

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Person with cancer—lung cancer immunohistochemistry type, code N[N]

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Lung cancer immunohistochemistry
METEOR identifier:	433027
Registration status:	Health , Standard 08/05/2014
Definition:	The type of immunohistochemistry stains used to assist in the identification of abnormal cells and hence the diagnosis of a person with cancer, as represented by a code.
Context:	This should be collected for people with cancer where pathology data is available.
Data Element Concept:	Person with cancer—immunohistochemistry type
Value Domain:	Lung cancer immunohistochemistry type code N[N]

Value domain attributes

Representational attributes

Representation class:	Code	
Data type:	Number	
Format:	N[N]	
Maximum character length:	2	
Permissible values:	Value	Meaning
	1	Thyroid transcription factor-1 (TTF-1)
	2	Cytokeratin 5 (CK5)
	3	Cytokeratin 6 (CK6)
	4	Cytokeratin 7 (CK7)
	5	Cytokeratin 20 (CK20)
	6	p53-related transcription factor p63 (p63)
	7	Napsin
Supplementary values:	88	Other
	97	Not applicable-immunohistochemical staining not performed
	98	Unknown if immunohistochemistry performed
	99	Immunohistochemistry performed but stains not stated/inadequately described

Collection and usage attributes

Guide for use:	Record the code for each immunohistochemical profile obtained to assist in the diagnosis of lung cancer.
-----------------------	----------------------------------------------------------------------------------------------------------

Comments: Thyroid transcription factor-1 and cytokeratin 7 and 20 can be useful, in conjunction with tumour morphology and clinical and radiological findings, to help to distinguish between primary and metastatic lung adenocarcinomas.

Cytokeratin 5/6 and p63 immunostaining is used by some pathologists to help to determine whether a tumour is a squamous or non-squamous type.

The majority (about 75%) of primary lung adenocarcinomas are CK7 positive, CK20 negative and TTF-1 positive and Napsin stains are positive in approximately 80% of primary lung adenocarcinomas.

Source and reference attributes

Submitting organisation: Cancer Australia

Reference documents: Royal College of Pathologists of Australasia 2010. Lung cancer structured reporting protocol. 1st Edition (Version 1.0). Surry Hills, NSW: Royal College of Pathologists of Australasia

Data element attributes

Collection and usage attributes

Guide for use: Record each [immunohistochemical](#) profile obtained to assist in the diagnosis of cancer.

When "other" is recorded, record the immunohistochemistry stain in text in [Person with cancer—immunohistochemistry type, text X\[49\]](#).

Collection methods: This information should be sought from the patient's medical record and may be included as a supplementary report in the original pathology report, or a stand-alone pathology report if a different laboratory performs the test.

Comments: Immunohistochemistry may be helpful in some instances for precise histological subclassification of the tumour and the exclusion of metastasis.

Source and reference attributes

Submitting organisation: Cancer Australia

Relational attributes

Related metadata references: See also [Person with cancer—immunohistochemistry type, text X\[X\(49\)\]](#)
[Health](#), Standard 08/05/2014

Implementation in Data Set Specifications: [Lung cancer \(clinical\) DSS](#)
[Health](#), Superseded 14/05/2015
Conditional obligation: Conditional on immunohistochemistry testing being completed.

[Lung cancer \(clinical\) NBPDS](#)
[Health](#), Standard 14/05/2015
Conditional obligation:

Conditional on immunohistochemistry testing being completed.